Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%

Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma’s Flector® (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

“We are excited to kick off the new year by launching the first of several products in our portfolio which includes authorized and complex generic medications,” said Stephen Beckman, CEO, Yaral Pharma. “Like Flector, Yaral Pharma’s diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment backed by more than 30 years of clinical experience. We are pleased to offer patients an accessible and affordable product that offers targeted topical pain relief and look forward to expanding our product line across a range of therapeutic areas in the months ahead.”

Yaral Pharma’s diclofenac epolamine topical system 1.3% patch (NDC 82347-0405-5) is currently available to order. For questions about ordering, contact Yaral Pharma at 1-866-218-9009.

Yaral Pharma has begun commercializing IBSA Pharma’s authorized generics and is poised to rapidly expand its product line organically through outside opportunities and external partnerships with a focus on oral solid dosage (OSD), complex and 505(b)2 products. The Company’s current portfolio includes products in the therapeutic areas of pain and endocrinology with future expansion planned in the areas of rheumatology, fertility/women's health, dermatology/dermo-aesthetic, and ophthalmology. For the latest updates on Yaral Pharma, visit www.yaral-pharma.com or connect with us on LinkedIn.

Please refer to the full Prescribing Information, including Boxed Warning for diclofenac epolamine topical system, 1.3% here.

You are encouraged to report suspected adverse reactions to Yaral Pharma by emailing MI@yaral-pharma.com or calling 866-218-9009 or to the FDA by visiting http://www.fda.gov/medwatch.

About Yaral Pharma

Yaral Pharma Inc. (Parsippany, NJ) is the US generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, Yaral Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, Yaral Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaral-pharma.com or contact info@yaral-pharma.com or 866-218-9009.